CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Authors
Keywords
-
Journal
NATURE BIOTECHNOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-23
DOI
10.1038/s41587-019-0192-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons
- (2018) Bryan D. Choi et al. Neurosurgical Focus
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143
- (2017) D. A. Reardon et al. NEURO-ONCOLOGY
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
- (2017) Nabil Ahmed et al. JAMA Oncology
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
- (2016) Kole T. Roybal et al. CELL
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
- (2015) H. G. Caruso et al. CANCER RESEARCH
- Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
- (2015) Chi-Ping Day et al. CELL
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma
- (2013) Bryan D. Choi et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody
- (2013) B. D. Choi et al. Cancer Immunology Research
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
- (2012) B. D. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bispecific antibodies engage T cells for antitumor immunotherapy
- (2011) Bryan D Choi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started